<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0102221665
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Emopack
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sofarimex Ind&#xFA;stria Qu&#xED;mica e Farmac&#xEA;utica, S.A.. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sofarimex Indústria Química e Farmacêutica, S.A.. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Emopack contains the active substance Omeprazole . It belongs to a group of medicines called &ldquo;proton<br />pump inhibitors&rdquo;. They work by reducing the amount of acid that your stomach produces.<br />Omeprazole can be used as an alternative to oral therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Emopack:</strong><br />&bull; if you are allergic (hypersensitive) to or any of the other ingredients of this medicine (listed<br />in section 6).<br />&bull; if you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lansoprazole,<br />rabeprazole, esomeprazole ).<br />&bull; if you are taking a medicine containing nelfinavir (used for HIV infection).<br />Do not use Emopack if any of the above applies to you. If you are not sure, talk to your doctor, nurse<br />or pharmacist before you are given this medicine.</p><p><strong>Warnings and precautions</strong><br />Emopack may hide the symptoms of other diseases. Therefore, if any of the following happen to you<br />before you are given Emopack or after you are given it, talk to your doctor straight away:<br />&bull; You lose a lot of weight for no reason and have problems swallowing.<br />&bull; You get stomach pain or indigestion.<br />&bull; You begin to vomit food or blood.<br />&bull; You pass black stools (blood-stained faeces).<br />&bull; You experience severe or persistent diarrhoea, as Omeprazole has been associated with a<br />small increase in infectious diarrhoea.<br />&bull; You have severe liver problems.</p><p>&bull; If you have ever had a skin reaction after treatment with a medicine similar to Omeprazole<br />that reduces stomach acid.<br />If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you<br />can, as you may need to stop your treatment with Omeprazole. Remember to also mention any other<br />ill-effects like pain in your joints.<br />Taking a proton pump inhibitor like Omeprazole, especially over a period of more than one year, may<br />slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have<br />osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).<br />Tell your doctor before taking this medicine, if:<br />&bull; You are due to have a specific blood test (Chromogranin A).</p><p><strong>Other medicines and Emopack</strong><br />Please tell your doctor, nurse or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription. This is because Emopack can affect<br />the way some medicines work and some medicines can have an effect on Emopack .<br />You must not be given Emopack if you are taking a medicine containing nelfinavir (used to treat<br />HIV infection).<br />Tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; Ketoconazole, itraconazole, posaconazole or voriconazole (used to treat infections caused by<br />a fungus).<br />&bull; Digoxin (used to treat heart problems)<br />&bull; Diazepam (used to treat anxiety, relax muscles or in epilepsy)<br />&bull; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor<br />you when you start or stop taking Omeprazole 40 mg powder for solution for infusion.<br />&bull; Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers.<br />Your doctor may need to monitor you when you start or stop taking Omeprazole<br />&bull; Rifampicin (used to treat tuberculosis)<br />&bull; Atazanavir (used to treat HIV infection)<br />&bull; Tacrolimus (in cases of organ transplantation)<br />&bull; St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression)<br />&bull; Cilostazol (used to treat intermittent claudication)<br />&bull; Saquinavir (used to treat HIV infection)<br />&bull; Clopidogrel (used to prevent blood clots (thrombi)<br />&bull; Erlotinib (used to treat cancer)<br />&bull; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are<br />taking a high dose of methotrexate, your doctor may temporarily stop your Omeprazole<br />treatment.<br />If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as Omeprazole to<br />treat ulcers caused by Helicobacter pylori infection, it is very important that you tell your doctor about<br />any other medicines you are taking.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />to your doctor or pharmacist for advice before taking this medicine.<br />Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses<br />are used. Your doctor will decide whether you can take Omeprazole if you are breastfeeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><br />Emopack is not likely to affect your ability to drive or use any tools or machines. Side effects such as<br />dizziness and visual disturbances may occur (see section 4). If affected, you should not drive or<br />operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Emopack can be given to adults including the elderly.<br />&bull; There is limited experience with Emopack for intravenous use in children.<br />&nbsp;</p><p><strong>Being given Emopack</strong><br />&bull; Emopack will be given to you by a doctor who will decide how much you need.<br />&bull; The medicine will be given to you as an infusion into one of your veins.</p><p><strong>If you use more Emopack than you should</strong><br />If you think you have been given too much Emopack , talk to your doctor straight away.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following rare but serious side effects, stop using Emopack and contact<br />a doctor immediately:</strong><br />&bull; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or<br />difficulties to swallow (severe allergic reaction).<br />&bull; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding<br />in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or<br />&lsquo;toxic epidermal necrolysis&rsquo;.<br />&bull; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.</p><p>Other side effects include:<br /><strong>Common side effects (may affect up to 1 in 10 people)</strong><br />&bull; Headache.<br />&bull; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).<br />&bull; Feeling sick (nausea) or being sick (vomiting).<br />&bull; Benign polyps in the stomach.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong><br />&bull; Swelling of the feet and ankles.<br />&bull; Disturbed sleep (insomnia).<br />&bull; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.<br />&bull; Spinning feeling (vertigo).<br />&bull; Changes in blood tests that check how the liver is working.<br />&bull; Skin rash, lumpy rash (hives) and itchy skin.<br />&bull; Generally feeling unwell and lacking energy.</p><p><strong>Rare side effects (may affect up to 1 in 1000 people)</strong><br />&bull; Blood problems such as a reduced number of white cells or platelets. This can cause<br />weakness, bruising or make infections more likely.</p><p>&bull; Allergic reactions, sometimes very severe, including swelling of the lips, tongue and throat,<br />fever, wheezing.<br />&bull; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and<br />cramps.<br />&bull; Feeling agitated, confused or depressed.<br />&bull; Taste changes.<br />&bull; Eyesight problems such as blurred vision.<br />&bull; Suddenly feeling wheezy or short of breath (bronchospasm).<br />&bull; Dry mouth.<br />&bull; An inflammation of the inside of the mouth.<br />&bull; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.<br />&bull; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.<br />&bull; Hair loss (alopecia).<br />&bull; Skin rash on exposure to sunshine.<br />&bull; Joint pains (arthralgia) or muscle pains (myalgia).<br />&bull; Severe kidney problems (interstitial nephritis).<br />&bull; Increased sweating.</p><p><strong>Very rare side effects (may affect up to 1 in 10 000 people)</strong><br />&bull; Changes in blood count including agranulocytosis (lack of white blood cells).<br />&bull; Aggression.<br />&bull; Seeing, feeling or hearing things that are not there (hallucinations).<br />&bull; Severe liver problems leading to liver failure and inflammation of the brain.<br />&bull; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a<br />high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic<br />epidermal necrolysis)<br />&bull; Muscle weakness.<br />&bull; Enlarged breasts in men.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong><br />&bull; Inflammation in the gut (leading to diarrhoea).<br />&bull; If you are on Omeprazole for more than three months it is possible that the levels of<br />magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue,<br />involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart<br />rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of<br />magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your<br />doctor may decide to perform regular blood tests to monitor your levels of magnesium.<br />&bull; Rash, possibly with pain in the joints</p><p>Irreversible visual impairment has been reported in isolated cases of critically ill patients who have<br />received Emopack intravenous injection, especially at high doses, but no causal relationship has been<br />established.</p><p>Omeprazole may in very rare cases affect the white blood cells leading to immune deficiency. If you<br />have an infection with symptoms such as fever with a severely reduced general condition or fever<br />with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating,<br />you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis)<br />can be ruled out by a blood test. It is important for you to give information about your medicine at<br />this time.</p><p>Do not be concerned by this list of possible side effects. You may not get any of them. If any of the<br />side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor<br />or pharmacist.<br />If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side<br />effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and the reach of children.</p><p>Do not store above 30&deg;C.<br />Do not use this medicine after the expiry date which is stated on the vial and carton after EXP. The<br />expiry date refers to the last day of that month.</p><p>Keep the vial in the outer carton in order to protect from light.<br />Shelf life after reconstitution: Solution for infusion reconstituted with sodium chloride 9 mg/ml<br />(0.9%) should be used within 12 hours after preparation. Solution for infusion reconstituted with<br />glucose 50 mg/ml (5%) should be used within 6 hours after preparation. From a microbiological point<br />of view, the product should be used immediately unless it has been reconstituted under controlled and<br />validated aseptic conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is Omeprazole. Each vial of powder for solution for intravenous infusion<br />contains Omeprazole sodium equivalent to 40 mg of Omeprazole.<br />- The other ingredients are disodium edetate and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Emopack (powder for infusion) comes in a vial.
Emopack is available in pack sizes of 1or 10 vials.
Not all pack sizes may be marketed.
The dry powder in the vial is made into a solution before it is given to you.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:<br />Sofarimex Ind&uacute;stria Qu&iacute;mica e Farmac&ecirc;utica, S.A.<br />Av. das Ind&uacute;strias- Alto do Colaride-Agualva<br />2735-213-Cac&eacute;m<br />Portugal<br />For</p><p>SPIMACO<br />Al-Qassim Pharmaceutical plant<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إيموباك يحتوي عل ى المادة الفعالة أوميبرازول. وه و ينتم ي إل ى مجموعة م ن الأدوية تسم ى &quot;مثبطا ت مضخة البروتو ن&quot;.<br />وه ي تعمل ع ن طريق تقليل كمية الأحماض الت ي تنتجها معدتك.<br />يمك ن استخدام أوميبرازول كبديل للعلاج ع ن طريق الفم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول إيموباك :</strong><br />.) &bull; إذا كن ت تعان ي م ن حساسية )أ و فرط الحساسية( لأي م ن المكونا ت الأخرى لهذا الدواء )المذكورة ف ي القسم 6<br />&bull; إذا كا ن لديك حساسية م ن أدوية مثبطا ت مضخة البروتو ن الأخرى )عل ى سبيل المثال ، بانتوبرازول ،<br />لانسوبرازول ، رابيبرازول ، وإيزوميبرازول(.<br />&bull; إذا كن ت تتناول دواء يحتوي على نيلفينافير)يستخدم لعلاج فيروس نقص المناعة البشرية(.<br />لا تستخدم إيموباك إذا كا ن أي مما سبق ينطبق عليك. إذا لم تك ن متأكد ا ، تحد ث مع طبيبك أ و الممرضة أ و الصيدل ي<br />قبل إعطاؤك هذا الدواء.<br />&nbsp;</p><p><strong>المحاذير والاحتياطا ت</strong><br />قد يخف ي إيموباك أعراض الأمراض الأخرى. لذلك ، إذا حد ث لك أي مما يل ي قبل إعطاؤك ال إيموباك أ و بعد إعطائه<br />، تحد ث إل ى طبيبك فور ا :<br />&bull; إذا كنت تفقد الكثير م ن الوز ن بدو ن سب ب ولديك مشاكل ف ي البلع.<br />&bull; إذا كنت تعان ي م ن ألم ف ي المعدة أ و عسر هضم.<br />&bull; إذا بدأت تتقيأ الطعام أ و الدم.<br />&bull; إذا أصبح لو ن البراز أسود )البراز الملو ن بالدم(.<br />&bull; إذا كن ت تعان ي م ن الإسهال الشديد أ و المستمر ، فقد ارتبط أوميبرازول بزيادة صغيرة ف ي نسبة حدوث الإسهال<br />المعدي.<br />&bull; لديك مشاكل خطيرة ف ي الكبد .<br />&bull; إذا كا ن لديك حاليا أو سابقا أي تفاعل جلدي بعد العلاج مع دواء مشابه ل أوميبراز ول يقلل م ن حمض المعدة.<br />إذا ظهر طف ح جلدي عل ى بشرتك ، خاصة ف ي المناطق المعرضة للشمس ، أخبر طبيبك بأسرع ما يمك ن ، حي ث قد<br />تحتاج إل ى إيقاف علاجك ب أوميبرازول. تذكر أي ضا ذكر أي أعراض مرضية أخرى مثل الألم ف ي مفاصلك.<br />قد يؤدي استخدام مثبط لمضخة البروتو ن مثل أوميبرازول ، خاصة خلال فترة تزيد ع ن عام واحد ، إل ى زيادة خطر<br />حدو ث الكسر بشكل طفيف ف ي الورك أ و المعصم أ و العمود الفقري. أخبر طبيبك إذا كن ت تعان ي م ن مرض<br />هشاشة العظام أ و إذا كن ت تتناول الكورتيكوستيرويدا ت )الت ي يمك ن أ ن تزيد م ن خطر الإصابة بهشاشة العظام( .</p><p>أخبر طبيبك قبل تناول هذا الدواء، إذا:<br />.) A &bull; كان م ن المقرر إجراء اختبار دم لك ل )كروموجرانين<br />&nbsp;</p><p><strong>أدوية أخرى و إيموبا ك</strong><br />م ن فضلك أخبر طبيبك أ و الممرضة أ و الصيدل ي إذا كن ت تتناول أ و تناول ت مؤخ را أي أدوية أخرى، بما ف ي ذلك<br />الأدوية الت ي تم الحصول عليها دو ن وصفة طبية. هذا لأ ن إيموباك يمك ن أ ن يؤثر عل ى طريقة عمل بعض الأدوية<br />وقد يكو ن لبعض الأدوية تأثير عل ى إيموباك.<br />يج ب عدم إعطاؤك إيموباك إذا كن ت تتناول دواء يحتوي عل ى نيلفينافير )يستخدم لعلاج عدوى فيروس العوز المناع ي<br />البشري - الإيدز(.<br />م ن فضلك أخبر طبيبك أ و أ و الصيدل ي إذا كن ت تتناول أي من الأدوية الآتية:<br />- كيتوكونازول ، إيتراكونازول ، بوزاكونازول أ و فورونيكونازول )يستخدم لعلاج الالتهابا ت الت ي يسببها الفطر( .<br />- الديجوكسي ن )يستخدم لعلاج مشاكل القل ب (<br />- الديازيبام )يستخدم لعلاج القلق أ و لاسترخاء العضلا ت أ و الصرع (<br />- الفينيتوي ن )يستخدم ف ي الصرع(. إذا كن ت تتناول الفينيت وي ن ، فسوف يحتاج طبيبك لمتابعتك عن كث ب عند بدء أ و التوقف<br />ع ن استخدام مسحوق أوميبرازول 40 لتحضير محلول الحقن بالتسري ب.<br />- الأدوية الت ي تستخدم لترقيق الدم ، مثل الوارفاري ن أ و غيرها م ن حاصرا ت فيتامي ن ك. قد يحتاج طبيبك لمتابعتك ع ن<br />كث ب عند بدء أ و التوقف ع ن تناول أوميبرازول<br />- ريفامبيسي ن )يستخدم لعلاج السل (<br />- اتازانافير )يستخدم لعلاج عدوى فيروس العوز المناع ي البشري(<br />- تاكروليمس )ف ي حالا ت زرع الأعضاء(<br />- نبتة سان ت جو ن )تستخدم لعلاج الاكتئا ب الخفيف(<br />- سيلوستازول )يستخدم لعلاج العرج المتقطع(<br />- ساكوينافير )يستخدم لعلاج عدوى فيروس العوز المناع ي البشري(<br />- كلوبيدوجريل )يستخدم لمنع الجلطا ت الدموية(<br />- إرلوتيني ب )يستخدم لعلاج السرطا ن(<br />- ميثوتريكسا ت )دواء علاج كيميائي يستخدم ف ي جرعا ت عالية لعلاج السرطا ن( - إذا كن ت تتناول جرعة كبيرة م ن<br />الميثوتريكسي ت ، قد يقوم طبيبك بإيقاف علاج أوميبرازول مؤقت ا.<br />إذا وصف لك طبيبك المضادا ت الحيوية اموكسيسيللي ن أ و كلاريثرومايسي ن مع أوميبرازول لعلاج القرح الناجمة ع ن<br />عدوى بكتريا هيليكوباكتربيلوري، فم ن المهم جد ا أ ن تخبر طبيبك عن أي أدوية أخرى تتناولها.<br />&nbsp;</p><p><strong>الحمل والرضاعة الطبيعي ة</strong><br />إذا كنت حاملا أ و ترضعي ن رضاعة طبيعية ، تعتقدي أنك قد تكونين حاملا أو تخططين لإنجاب طفل ، اسأل ي طبيبك أو<br />الصيدلي للحصول على المشورة قبل تناول هذا الدواء.<br />يفرز أوميبرازول ف ي حلي ب الثدي ولك ن ليس م ن المرج ح أ ن يؤثر عل ى الطفل عند استخدام الجرعا ت العلاجية. سيقرر<br />طبيبك ما إذا كا ن بإمكانك تناول أوميبرازول إذا كن ت ترضعي ن طفلك رضاعة طبيعية.</p><p><strong>القيادة واستخدام الآلات</strong><br />م ن غير المرج ح أ ن يؤثر إيموباك عل ى قدرتك عل ى قيادة أ و استخدام أي أدوا ت أ و آلا ت. قد تحد ث تأثيرا ت جانبية مثل<br />الدوخة والاضطرابا ت البصرية )انظر القسم 4(. إذا تأثرت، يج ب عليك عدم قيادة السيارة أ و تشغيل الآلا ت.<br />&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يمك ن إعطاء إيموباك للبالغي ن بما ف ي ذلك كبار الس ن.<br />&bull; هناك معلوما ت محدودة مع لاستخدام إيموباك الوريدي ف ي الأطفال.</p><p>كيف يعط ى الإيموباك<br />&bull; سيتم إعطائك إيموباك م ن قبل الطبي ب الذي سيقرر مقدار ما تحتاجه.<br />&bull; سيتم إعطاءك الدواء كحق ن ف ي أحد الأوردة.</p><p><strong>الجرعة الزائد ة</strong><br />إذا كن ت تعتقد أنك قد أعطي ت الكثير م ن إيموباك ، تحد ث إل ى طبيبك عل ى الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء أعراضا جانبية ، على الرغم من عدم تعرض الجميع لها.<br /><strong>توقف عن </strong>تناول إيموباك عل ى الفور واتصل بطبيبك في حالة حدوث أي من هذه الأعراض الخطيرة النادرة :<br />&bull; أزيز شديد، تورم ف ي الشفاه واللسا ن والحلق أ و الجسم أ و طف ح جلدي أ و إغماء أ و صعوبا ت ف ي البلع )فرط<br />الحساسية( .<br />&bull; احمرار الجلد بثور أ و تقشير. قد يكو ن هناك أيضا بثور شديدة ونزيف ف ي الشفتي ن والعيني ن والفم والأنف<br />والأعضاء التناسلية. يمك ن أ ن يكو ن هذا ما يدع ى &quot;متلازمة ستيفنز جونسو ن&quot; أ و &quot;انحلال البشرة السم ي&quot;.<br />&bull; البشرة الصفراء والبول الداك ن والتع ب والت ي يمك ن أ ن تكو ن م ن أعراض مشاكل الكبد .<br />تشمل الأعراض الجانبية الأخرى:</p><p>الأعراض الجانبية الشائعة )قد تؤثر عل ى 1 م ن كل 10 أشخاص (<br />&bull; صداع الرأس .<br />&bull; أعراض المعدة أ و القناة الهضمية: الإسهال، آلام ف ي المعدة، والإمساك، والري ح )انتفاخ البط ن(.<br />&bull; الشعور بالغثيا ن أ و المرض )التقيؤ(.<br />&bull; الأورام الحميدة ف ي المعدة.</p><p>أعراض جانبية غير شائعة )قد تؤثر عل ى 1 م ن كل 100 شخص (<br />&bull; تورم القدمي ن والكاحلي ن.<br />&bull; اضطرا ب النوم )الأرق(.<br />&bull; دوار، شعور بالوخز مثل &quot;دبابيس وإبر&quot;، الشعور بالنعاس.<br />&bull; الشعور بالدوار )الدوخة(.<br />&bull; التغييرا ت ف ي اختبارا ت الدم الت ي تتحقق م ن كيفية عمل الكبد.<br />&bull; الطف ح الجلدي و الشري وحكة الجلد.<br />&bull; الشعور العام بالمرض وانعدام الطاقة.</p><p>الأعراض الجانبية النادرة )قد تؤثر عل ى 1 م ن كل 1000 شخص (<br />&bull; مشاكل الدم مثل انخفاض عدد الخلايا البيضاء أ و الصفائ ح الدموية. هذا يمك ن أ ن يسب ب الضعف، وكدما ت أ و<br />جعل العدوى أكثر احتمالا.<br />&bull; ردود الفعل التحسسية ، وأحيان ا شديدة جد ا ، بما ف ي ذلك تورم الشفاه واللسا ن والحلق والحم ى والأزيز.<br />&bull; مستويا ت منخفضة م ن الصوديوم ف ي الدم. قد يتسب ب ذلك ف ي الضعف والمرض )التقي ؤ( وتشنجا ت.<br />&bull; الشعور بالتهي ج أ و الارتباك أ و الاكتئا ب.<br />&bull; تغيرا ت في حاسة التذوق.<br />&bull; مشاكل ف ي البصر مثل عدم وضوح الرؤية.<br />&bull; الشعور فجأة بالتوه ج أ و قصر التنفس )تقلص الشع ب(.<br />&bull; جفاف الفم.<br />&bull; التها ب داخل الفم.<br />&bull; عدوى تسم ى &quot;القلاع&quot; الت ي يمك ن أ ن تؤثر عل ى القناة الهضمية وتنت ج ع ن فطر.<br />&bull; مشاكل الكبد، بما ف ي ذلك اليرقا ن الذي يمك ن أ ن يسب ب لون الجلد الأصفر والبول الداك ن والتع ب.<br />&bull; تساقط الشعر )الصلع( .<br />&bull; الطف ح الجلدي عند التعرض لأشعة الشمس .<br />&bull; آلام ف ي المفاصل )ألم مفصل ي( أ و آلام ف ي العضلا ت )ألم عضل ي(.<br />&bull; مشاكل الكل ى الحادة )التها ب الكلية الخلال ي( .<br />&bull; زيادة التعرق.</p><p>أعراض جانبية نادرة جدا )قد تؤثر عل ى 1 م ن كل 10 آلاف شخص (<br />&bull; التغيرا ت ف ي عدد خلايا الدم بما ف ي ذلك ندرة المحببا ت )نقص خلايا الدم البيضاء(.<br />&bull; العدائية.<br />&bull; رؤية أ و شعور أ و سماع أشياء غير موجودة )الهلاوس( .</p><p>&bull; مشاكل الكبد الحادة الت ي تؤدي إل ى فشل الكبد والالتها ب ف ي الدماغ.<br />&bull; ظهور مفاج ئ لطف ح جلدي حاد أ و تقرحا ت أ و تقشير الجلد. قد يكو ن هذا مرتب طا بحم ى مرتفعة وآلام ف ي<br />المفاصل )حُمامَ ى عَديدَة الأَشْكال ، متلازمة ستيفنز جونسو ن، تَقَشُّرُ الأَنْسِجَةِ المُتَمَ وِتَةِ البَشْرَوِيَّةِ التَّسَمُّمِ ي(<br />&bull; ضعف العضلا ت .<br />&bull; تضخم الثديي ن عند الرجال.</p><p>غير معروف )لا يمك ن تقدير التردد م ن البيانا ت المتاحة(<br />&bull; التها ب ف ي القناة الهضمية )مما يؤدي إل ى الإسهال(.<br />&bull; إذا كنت تتناول أوميبراز ول أكثر م ن ثلاثة أشهر ، فم ن الممك ن أ ن تنخفض مستويا ت المغنيسيوم ف ي دمك.<br />يمك ن أ ن يسب ب نقص المغنيسيوم التع ب ، وتقلصا ت العضلا ت اللاإرادية ، والارتباك ، والتشنجا ت ، والدوخة<br />أ و زيادة معدل ضربا ت القل ب. إذا تعرض ت ل أي م ن هذه الأعراض ، يرج ى إخبار طبيبك عل ى الفور. يمك ن<br />أ ن يؤدي انخفاض مستويا ت المغنيسيوم أي ضا إل ى انخفاض مستويات البوتاسيوم أ و الكالسيوم ف ي الدم. قد يقرر<br />طبيبك إجراء اختبارا ت دم منتظمة لمراقبة مستويا ت المغنيسيوم.<br />&bull; الطف ح ، ربما مع ألم ف ي المفاص ل<br />تم الإبلاغ ع ن ضعف بصري مستديم ف ي حالا ت محدودة م ن المرض ى ذوي الحالا ت الحرجة الذي ن تلقوا الحق ن<br />بالتسري ب ب إيموباك ، وخاصة ف ي الجرعا ت العالية ، ولك ن لم يتم تحديد علاقة سببية.</p><p>قد يؤثر أوميبرازول ف ي حالا ت نادرة جد ا عل ى خلايا الدم البيضاء الت ي تؤدي إل ى نقص المناعة. إذا كا ن لديك عدوى<br />مع أعراض مثل الحم ى مع ضعف عام شديد أ و حم ى مع أعراض عدوى محلية مثل ألم ف ي الرقبة أ و الحلق أ و الفم أ و<br />صعوبا ت ف ي التبول ، يج ب استشارة طبيبك ف ي أقر ب وق ت ممك ن حت ى يمك ن استبعاد نقص خلايا الدم البيضاء )ندرة<br />المحببا ت( ع ن طريق فحص الدم. م ن المهم ف ي هذه الحالة معرفة الدواء.<br />لا تقلق م ن هذه القائمة م ن الأعراض الجانبية المحتملة. قد لا تتعرض لأي منها. إذا كان ت أي م ن الأعراض الجانبية<br />خطيرة، أ و إذا لاحظ ت أي أعراض جانبية غير مدرجة ف ي هذه النشرة، يرج ى إخبار طبيبك أ و الصيدل ي.<br />إذا تعرض ت ل أي أعراض جانبية، تحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي أعراض جانبية<br />محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- ابق هذا الدواء بعيدا عن متناول ونظر الأطفال .<br />- لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.<br />- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على الكرتون الخارجي، والغلاف والشريط ، بعد<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر. .EXP كلمة<br />- احفظ القنينة ف ي الكرتو ن الخارج ي م ن أجل الحماية م ن الضوء.<br />- مدة الصلاحية بعد إعادة التركي ب: يج ب استخدام المحلول المحضر مع كلوريد الصوديوم 9 ملجم / مل<br />٪0.9 ( خلال 12 ساعة بعد التحضير. (<br />- يج ب استخدام المحلول المحضر مع الجلوكوز 50 ملجم لكل مل ) 5٪( خلال 6 ساعا ت بعد التحضير.<br />- م ن وجهة نظر ميكروبيولوجية ، يج ب استخدام المحلول عل ى الفور ما لم يكن قد تم تحضيره تح ت ظروف<br />معقمة خاضعة للرقابة ومحققة.<br />- لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية<br />التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة ه ي أوميبرازول. كل قنينة م ن مسحوق المعد لتحضير محلول الحق ن الوريدي بالتسري ب تحتوي عل ى<br />أوميبرازول الصوديوم يعادل 40 ملجم م ن أوميبرازول.<br />- المكونا ت الأخرى ه ي ايديتي ت الصوديوم وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">يأت ي مسحوق إيموباك المعد لتحضير محلول للحقن بالتسري ب ف ي قنينة.<br />إيموباك متاح ف ي أحجام علبة 1 أو 10 قنينا ت.</p><p style="text-align:right">قد لا يتم تسويق جميع أحجام العبوا ت.<br />المسحوق الجاف ف ي القنينة يستخدم لتحضير محلول قبل إعطاؤه لك .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المصنع:<br />سوفيريميكس اندستريا كيوميكا فارماسيوتيكا<br />اف داس اندستريا - التو دو كولاريد - اجوالفا<br />-213-2735 كاس م<br />البرتغال<br />لصال ح<br />الدوائية<br />مصنع الأدوية بالقصيم<br />المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emopack 40 mg powder for solution for intravenous infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 42.6 mg of omeprazole sodium equivalent to 40 mg of
omeprazole. After reconstitution and dilution, 1 ml of solution contains 0.426
mg of omeprazole sodium equivalent to 0.4 mg of omeprazole.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion (Powder for infusion) pH interval in glucose is
approximately 8.9-9.5 and in sodium chloride 0.9%, 9.3-10.3.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omeprazole 40 mg powder for solution for infusion for intravenous use is<br />indicated as an alternative to oral therapy for the following indications i.e.<br /><u>Adults</u><br />&bull; Treatment of duodenal ulcers<br />&bull; Prevention of relapse of duodenal ulcers<br />&bull; Treatment of gastric ulcers<br />&bull; Prevention of relapse of gastric ulcers<br />&bull; In combination with appropriate antibiotics, Helicobacter pylori (H.<br />pylori) eradication in peptic ulcer disease<br />&bull; Treatment of NSAID-associated gastric and duodenal ulcers<br />&bull; Prevention of NSAID-associated gastric and duodenal ulcers in patients<br />at risk<br />&bull; Treatment of reflux esophagitis<br />&bull; Long-term management of patients with healed reflux esophagitis<br />&bull; Treatment of symptomatic gastro-esophageal reflux disease<br />&bull; Treatment of Zollinger-Ellison syndrome</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br /><em>Alternative to oral therapy</em><br />In patients where the use of oral medicinal products is inappropriate,<br />Omeprazole 40 mg powder for solution for infusion IV 40 mg once daily is<br />recommended. In patients with Zollinger-Ellison Syndrome the recommended<br />initial dose of Omeprazole 40 mg powder for solution for infusion given<br />intravenously is 60 mg daily. Higher daily doses may be required and the dose<br />should be adjusted individually. When doses exceed 60 mg daily, the dose<br />should be divided and given twice daily.<br />Omeprazole 40 mg powder for solution for infusion is to be administered in an<br />intravenous infusion for 20-30 minutes.<br />For instructions on reconstitution of the product before administration, see<br />section 6.6.<br /><u>Special populations</u><br /><em>Impaired renal function</em><br />Dose adjustment is not needed in patients with impaired renal function. (see<br />section 5.2).<br /><em>Impaired hepatic function</em><br />In patients with impaired hepatic function a daily dose of 10-20 mg may be<br />sufficient (see section 5.2).<br /><em>Older people (&gt; 65 years old)</em><br />Dose adjustment is not needed in the elderly (see section 5.2).<br /><em>Paediatric population</em><br />There is limited experience with Omeprazole 40 mg powder for solution for<br />infusion for intravenous use in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to omeprazole, substituted benzimidazoles or to any of the
excipients.
Omeprazole like other proton pump inhibitors (PPIs) should not be used
concomitantly with nelfinavir (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptoms (eg, significant unintentional weight<br />loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric<br />ulcer is suspected or present, malignancy should be excluded, as treatment may<br />alleviate symptoms and delay diagnosis.<br />Co-administration of atazanavir with proton pump inhibitors is not<br />recommended (see section 4.5). If the combination of atazanavir with a proton<br />pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load)<br />is recommended in combination with an increase in the dose of atazanavir to<br />400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded.<br />Omeprazole, as all acid-blocking medicines, may reduce the absorption of<br />vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be<br />considered in patients with reduced body stores or risk factors for reduced<br />vitamin B12 absorption on long-term therapy.<br />Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with<br />omeprazole, the potential for interactions with drugs metabolised through<br />CYP2C19 should be considered. An interaction is observed between<br />clopidogrel and omeprazole (see section 4.5). The clinical relevance of this<br />interaction is uncertain. As a precaution, concomitant use of omeprazole and<br />clopidogrel should be avoided.<br />Treatment with proton pump inhibitors may lead to slightly increased risk of<br />gastrointestinal infections such as Salmonella and Campylobacter (see section<br />5.1).<br />Severe hypomagnesaemia has been reported in patients treated with proton<br />pump inhibitors (PPIs) like omeprazole for at least three months, and in most<br />cases for a year. Serious manifestations of hypomagnesaemia such as fatigue,<br />tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur<br />but they may begin insidiously and be overlooked. In most affected patients,</p><p>hypomagnesaemia improved after magnesium replacement and discontinuation<br />of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with<br />digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare<br />professionals should consider measuring magnesium levels before starting PPI<br />treatment and periodically during treatment.<br />Proton pump inhibitors, especially if used in high doses and over long durations<br />(&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture,<br />predominantly in the elderly or in presence of other recognised risk factors.<br />Observational studies suggest that proton pump inhibitors may increase the<br />overall risk of fracture by 10-40%. Some of this increase may be due to other<br />risk factors.<br />Patients at risk of osteoporosis should receive care according to current clinical<br />guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>Interference with laboratory tests<br />Increased Chromogranin A (CgA) level may interfere with investigations for<br />neuroendocrine tumours. To avoid this interference, Omeprazole Azevedos<br />treatment should be stopped for at least 5 days before CgA measurements (see<br />section 5.1). If CgA and gastrin levels have not returned to reference range after<br />initial measurement, measurements should be repeated 14 days after cessation<br />of proton pump inhibitor treatment.</p><p>As in all long-term treatments, especially when exceeding a treatment period of<br />1 year, patients should be kept under regular surveillance.</p><p>Subacute cutaneous lupus erythematosus (SCLE)<br />Proton pump inhibitors are associated with very infrequent cases of SCLE. If<br />lesions occur, especially in sun-exposed areas of the skin, and if accompanied<br />by arthralgia, the patient should seek medical help promptly and the health care<br />professional should consider stopping Omeprazole. SCLE after previous<br />treatment with a proton pump inhibitor may increase the risk of SCLE with other<br />proton pump inhibitors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of omeprazole on the pharmacokinetics of other active substances</u><br />&nbsp;</p><p><em><u>Active substances with pH dependent absorption</u></em><br />The decreased intragastric acidity during treatment with omeprazole might<br />increase or decrease the absorption of active substances with a gastric pH<br />dependent absorption.</p><p><em>Nelfinavir, atazanavir</em><br />The plasma levels of nelfinavir and atazanavir are decreased in case of coadministration<br />with omeprazole.<br />Concomitant administration of omeprazole with nelfinavir is contraindicated<br />(see section 4.3). Co-administration of omeprazole (40 mg once daily) reduced<br />mean nelvinavir exposure by ca. 40% and the mean exposure of the<br />pharmacologically active metabolite M8 was reduced by ca. 75-90%. The<br />interaction may also involve CYP2C19 inhibition.<br />Concomitant administration of omeprazole with atazanavir is not recommended<br />(see section 4.4). Concomitant administration of omeprazole (40 mg once daily)<br />and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a 75%<br />decrease of the atazanavir exposure. Increasing the atazanavir dose to 400 mg<br />did not compensate for the impact of omeprazole on atazanavir exposure. The<br />co-administration of omeprazole (20 mg once daily) with atazanavir 400<br />mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of<br />approximately 30% in the atazanavir exposure as compared to atazanavir 300<br />mg/ritonavir 100 mg once daily.</p><p><em>Digoxin</em><br />Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy<br />subjects increased the bioavailability of digoxin by 10%. Digoxin toxicity has<br />been rarely reported. However caution should be exercised when omeprazole is<br />given at high doses in elderly patients. Therapeutic drug monitoring of digoxin<br />should be then be reinforced.</p><p>&nbsp;</p><p><em>Clopidogrel</em><br />Result from studies in healthy subjects have shown a pharmacokinetics<br />(PK/pharmacodynamic (PD) iteraction between clopidogrel (330 mg loading<br />dose/ 75 mg daily maintenance dose) and omeprazole (80 mg p.o. daily)<br />resulting in a decreased exposure to the active metabolite of clopidogrel by an<br />average of 46% and a decreased maximum inhibition of (ADP induced) platelet<br />aggregation by an average of 16%.<br />Inconsistent data on the clinical implications of this PK/PD interaction of<br />omeprazole in terms of major cardiovascular events have been reported from<br />observational and clinical studies. As precaution, concomitant use of<br />omeprazole and clopidogrel should be discouraged (see section 4.4).<br />&nbsp;</p><p><em>Other active substances</em><br />The absorption of posaconazole, erlotinib, ketoconazol and itraconazol is<br />significantly reduced and thus clinical efficacy may be impaired. For<br />posaconazol and erlotinib concomitant use should be avoided.</p><p><u><em>Active substances metabolised by CYP2C19</em></u><br />Omeprazole is a moderate inhibitor of CYP2C19, the major omeprazole<br />metabolising enzyme. Thus, the metabolism of concomitant active substances<br />also metabolised by CYP2C19, may be decreased and the systemic exposure to<br />these substances increased. Examples of such drugs are R-warfarin and other<br />vitamin K antagonists, cilostazol, diazepam and phenytoin.<br />&nbsp;</p><p><em>Cilostazol</em><br />Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study,<br />increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one<br />of its active metabolites by 29% and 69% respectively.<br />&nbsp;</p><p><em>Phenytoin</em><br />Monitoring phenytoin plasma concentration is recommended during the first<br />two weeks after initiating omeprazole treatment and, if a phenytoin dose<br />adjustment is made, monitoring and a further dose adjustment should occur<br />upon ending omeprazole treatment.</p><p>&nbsp;</p><p><em><u>Unknown mechanism</u></em><br />&nbsp;</p><p><em>Saquinavir</em><br />Concomitant administration of omeprazole with saquinavir/ritonavir resulted in<br />increased plasma levels up to approximately 70% for saquinavir associated with<br />good tolerability in HIV-infected patients.</p><p><em>Tacrolimus</em><br />Concomitant administration of omeprazole has been reported to increase the<br />serum levels of tacrolimus. A reinforced monitoring of tacrolimus<br />concentrations as well as renal function (creatinine clearance) should be<br />performed, and dosage of tacrolimus adjusted if needed.</p><p>Methotrexate<br />When given together with proton-pump inhibitors, methotrexate levels have<br />been reported to increase in some patients. In high-dose methotrexate<br />administration a temporary withdrawal of omeprazole may need to be<br />considered.<br />&nbsp;</p><p><u>Effects of other active substances on the pharmacokinetics of omeprazole</u><br />&nbsp;</p><p><u><em>Inhibitors of CYP2C19 and/or CYP3A4</em></u><br />Since omeprazole is metabolised by CYP2C19 and CYP3A4, active substances<br />known to inhibit CYP2C19 or CYP3A4 (such as clarithromycin and<br />voriconazole) may lead to increased omeprazole serum levels by decreasing<br />omeprazole&rsquo;s rate of metabolism. Concomitant voriconazole treatment resulted<br />in more than doubling of the omeprazole exposure. As high doses of omeprazole<br />have been well-tolerated adjustment of the omeprazole dose is not generally<br />required. However, dose adjustment should be considered in patients with<br />severe hepatic impairment and if long-term treatment is indicated.<br />&nbsp;</p><p><u><em>Inducers of CYP2C19 and/or CYP3A4</em></u><br />Active substances known to induce CYP2C19 or CYP3A4 or both (such as<br />rifampicin and St John&rsquo;s wort) may lead to decreased omeprazole serum levels<br />by increasing omeprazole&rsquo;s rate of metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Results from three prospective epidemiological studies (more than 1000<br />exposed outcomes) indicate no adverse effects of omeprazole on pregnancy or<br />on the health of the foetus/newborn child. Omeprazole can be used during<br />pregnancy.<br />Breastfeeding<br />Omeprazole is excreted in breast milk but is not likely to influence the child<br />when therapeutic doses are used.<br />Fertility<br />Animal studies with the racemic mixture omeprazole, given by oral<br />administration do not indicate effects with respect to fertility.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omeprazole 40 mg powder for solution for infusion is not likely to affect the<br />ability to drive or use machines. Adverse drug reactions such as dizziness and<br />visual disturbances may occur (see section 4.8). If affected, patients should not<br />drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile<br />The most common side effects (1-10% of patients) are headache, abdominal<br />pain, constipation, diarrhoea, flatulence and nausea/vomiting.<br />Tabulated list of adverse reactions<br />The following adverse drug reactions have been identified or suspected in the<br />clinical trials programme for omeprazole and post-marketing. None was found<br />to be dose-related. Adverse reactions listed below are classified according to<br />frequency and System Organ Class (SOC). Frequency categories are defined<br />according to the following convention: Very common (&ge; 1/10), Common (&ge;<br />1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt;<br />1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be estimated from the<br />available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>SOC/frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Veryrare:</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immunesystemdisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and</p><p>anaphylactic reaction/shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolismandnutritiondisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Notknown:</p></td><td style="vertical-align:top"><p>Hypomagnesaemia; severe hypomagnesaemia may result in</p><p>hypocalcaemia.</p><p>Hypomagnesaemia may also be associated with hypokalaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatricdisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Insomnia&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>Veryrare:</p></td><td style="vertical-align:top"><p>Aggression, hallucinations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervoussystemdisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Tastedisturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eyedisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Blurredvision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Earandlabyrinthdisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, diarrhoea, flatulence,</p><p>nausea/vomiting, fundic gland polyps (benign)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dry mouth, stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Notknown:</p></td><td style="vertical-align:top"><p>Microscopiccolitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliarydisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increasedliverenzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Veryrare:</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing</p><p>liver disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Alopecia, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Veryrare:</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome,</p><p>toxicepidermalnecrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>Notknown</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Veryrare:</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal andurinarydisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Interstitialnephritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Veryrare:</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malaise, peripheraloedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Increasedsweating</p></td></tr></tbody></table><p>&nbsp;</p><p>Irreversible visual impairment has been reported in isolated cases of critically ill<br />patients who have received omeprazole intravenous injection, especially at high doses,<br />but no causal relationship has been established.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p></td></tr><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available on the effects of overdoses of omeprazole<br />in humans. In the literature, doses of up to 560 mg have been described, and<br />occasional reports have been received when single oral doses have reached up<br />to 2,400 mg omeprazole (120 times the usual recommended clinical dose).<br />Nausea, vomiting, dizziness, abdominal pain, diarrhoea and headache have been<br />reported. Also apathy, depression and confusion have been described in single<br />cases.<br />The symptoms described have been transient, and no serious outcome has been<br />reported. The rate of elimination was unchanged (first order kinetics) with<br />increased doses. Treatment, if needed, is symptomatic.<br />Intravenous doses of up to 270 mg on a single day and up to 650 mg over a<br />three-day period have been given in clinical trials without any dose-related<br />adverse reactions.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC01<br />&nbsp;</p><p><u>Mechanism of action</u><br />Omeprazole, a racemic mixture of two enantiomers reduces gastric acid<br />secretion through a highly targeted mechanism of action. It is a specific inhibitor<br />of the acid pump in the parietal cell. It is rapidly acting and provides control<br />through reversible inhibition of gastric acid secretion with once-daily dosing.</p><p>Omeprazole is a weak base and is concentrated and converted to the active form<br />in the highly acidic environment of the intracellular canaliculi within the parietal<br />cell, where it inhibits the enzyme H+,K+-ATPase - the acid pump. This effect<br />on the final step of the gastric acid formation process is dose-dependent and<br />provides for highly effective inhibition of both basal acid secretion and<br />stimulated acid secretion, irrespective of stimulus.<br />&nbsp;</p><p><em><u>Pharmacodynamic effects</u></em><br />All pharmacodynamic effects observed can be explained by the effect of<br />omeprazole on acid secretion.</p><p><em>Effect on gastric acid secretion</em><br />Intravenous omeprazole produces a dose dependent inhibition of gastric acid<br />secretion in humans. In order to immediately achieve a similar reduction of<br />intragastric acidity as after repeated dosing with 20 mg orally, a first dose of 40<br />mg intravenously is recommended. This results in an immediate decrease in<br />intragastric acidity and a mean decrease over 24 hours of approximately 90%<br />for both iv injection and iv infusion.<br />The inhibition of acid secretion is related to the area under the plasma<br />concentration-time curve (AUC) of omeprazole and not to the actual plasma<br />concentration at a given time.<br />No tachyphylaxis has been observed during treatment with omeprazole.</p><p><em>Effect on H. pylori</em><br />H. pylori is associated with peptic ulcer disease, including duodenal and gastric<br />ulcer disease. H. pylori is a major factor in the development of gastritis. H.<br />pylori together with gastric acid are major factors in the development of peptic<br />ulcer disease. H. pylori is a major factor in the development of atrophic gastritis<br />which is associated with an increased risk of developing gastric cancer.<br />Eradication of H. pylori with omeprazole and antimicrobials is associated with<br />high rates of healing and long-term remission of peptic ulcers.</p><p><em>Other effects related to acid inhibition</em><br />During long-term treatment gastric glandular cysts have been reported in a<br />somewhat increased frequency. These changes are a physiological consequence</p><p>of pronounced inhibition of acid secretion, are benign and appear to be<br />reversible.<br />Decreased gastric acidity due to any means including proton pump inhibitors,<br />increases gastric counts of bacteria normally present in the gastrointestinal tract.<br />Treatment with acid-reducing drugs may lead to slightly increased risk of<br />gastrointestinal infections such as Salmonella and Campylobacter.<br />During treatment with antisecretory medicinal products, serum gastrin increases<br />in response to the decreased acid secretion. Also CgA increases due to decreased<br />gastric acidity. The increased CgA level may interfere with investigations for<br />neuroendocrine tumors. Literature reports indicate that proton pump inhibitor<br />treatment should be stopped at least 5 days before CgA measurements should<br />be repeated 14 days after cessation of omeprazole treatment.<br />An increased number of ECL cells possibly related to the increased serum<br />gastrin levels, have been observed in some patients (both children and adults)<br />during long term treatment with omeprazole. The findings are considered to be<br />of no clinical significance.<br />During treatment with antisecretory medicinal products, serum gastrin increases<br />in response to the decreased acid secretion. Also CgA increases due to decreased<br />gastric acidity. The increased CgA level may interfere with investigations for<br />neuroendocrine tumours.<br />Available published evidence suggests that proton pump inhibitors should be<br />discontinued between 5 days and 2 weeks prior to CgA measurements. This is<br />to allow CgA levels that might be spuriously elevated following PPI treatment<br />to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u><br />The apparent volume of distribution in healthy subjects is approximately 0.3<br />l/kg body weight. Omeprazole is 97% plasma protein bound.</p><p>Biotransformation<br />Omeprazole is completely metabolised by the cytochrome P450 system (CYP).<br />The major part of its metabolism is dependent on the polymorphically expressed<br />CYP2C19, responsible for the formation of hydroxyomeprazole, the major<br />metabolite in plasma. The remaining part is dependent on another specific<br />isoform, CYP3A4, responsible for the formation of omeprazole sulphone. As a</p><p>consequence of high affinity of omeprazole to CYP2C19, there is a potential for<br />competitive inhibition and metabolic drug-drug interactions with other<br />substrates for CYP2C19. However, due to low affinity to CYP3A4, omeprazole<br />has no potential to inhibit the metabolism of other CYP3A4 substrates. In<br />addition, omeprazole lacks an inhibitory effect on the main CYP enzymes.<br />Approximately 3% of the Caucasian population and 15&ndash;20% of Asian<br />populations lack a functional CYP2C19 enzyme and are called poor<br />metabolisers. In such individuals the metabolism of omeprazole is probably<br />mainly catalysed by CYP3A4. After repeated once-daily administration of 20<br />mg omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers<br />than in subjects having a functional CYP2C19 enzyme (extensive metabolisers).<br />Mean peak plasma concentrations were also higher, by 3 to 5 times. These<br />findings have no implications for the posology of omeprazole.</p><p><u>Elimination</u>Total plasma clearance is about 30-40 l/h after a single dose. The<br />plasma elimination half-life of omeprazole is usually shorter than one hour both<br />after single and repeated once-daily dosing. Omeprazole is completely<br />eliminated from plasma between doses with no tendency for accumulation<br />during once-daily administration. Almost 80% of a dose of omeprazole is<br />excreted as metabolites in the urine, the remainder in the faeces, primarily<br />originating from bile secretion.</p><p>Linearity/non-linearity<br />The AUC of omeprazole increases with repeated administration. This increase<br />is dose-dependent and results in a non-linear dose-AUC relationship after<br />repeated administration. This time- and dose-dependency is due to a decrease<br />of first pass metabolism and systemic clearance probably caused by an<br />inhibition of the CYP2C19 enzyme by omeprazole and/or its metabolites (e.g.<br />the sulphone).<br />No metabolite has been found to have any effect on gastric acid secretion.<br />&nbsp;</p><p><u>Special populations</u><br /><em>Impaired hepatic function</em><br />The metabolism of omeprazole in patients with liver dysfunction is impaired,<br />resulting in an increased AUC. Omeprazole has not shown any tendency to<br />accumulate with once-daily dosing.</p><p><em>Impaired renal function</em><br />The pharmacokinetics of omeprazole, including systemic bioavailability and<br />elimination rate, are unchanged in patients with reduced renal function.</p><p><em>Older people</em> The metabolism rate of omeprazole is somewhat reduced in<br />elderly subjects (75-79 years of age).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long<br />studies in rats treated with omeprazole. These changes are the result of sustained<br />hypergastrinaemia secondary to acid inhibition. Similar findings have been<br />made after treatment with H2-receptor antagonists, proton pump inhibitors and<br />after partial fundectomy. Thus, these changes are not from a direct effect of any<br />individual active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium edetate,<br />Sodium hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be mixed with other medicinal products than<br />those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened packs: 2 years.
Reconstituted solution:
Chemical and physical in-use stability has been demonstrated for 12 hours at
25°C after reconstitution with sodium chloride 9 mg/ml (0.9%) solution for
infusion and for 6 hours at 25°C after reconstitution with glucose 50 mg/ml (5%)
solution for infusion.
From a microbiological point of view, the product should be used immediately
unless it has been reconstituted under controlled and validated aseptic
conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the vial in the outer carton in order to protect from light. Vials can however<br />be stored exposed to normal indoor light outside the box for up to 24 hours.<br />Do not store above 30&deg;C<br />For storage conditions after reconstitution of the medicinal product, see section<br />6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial made of colourless borosilicate glass, typeI. Stopper made of chlorobutyl<br />rubber, cap made of aluminium and a plastic polypropylene lid.<br />Pack sizes: 1 Vial and 10 Vials.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The entire contents of each vial is to be dissolved in approximately 5 ml and<br />then immediately diluted to 100 ml. Sodium chloride 9 mg/ml (0.9%) solution<br />for infusion or glucose 50 mg/ml (5%) solution for infusion must be used. The<br />stability of omeprazole is influenced by the pH of the solution for infusion,<br />which is why no other solvent or quantities should be used for dilution.</p><p><u>Preparation</u><br />1. With a syringe draw 5 ml of infusion solution from the 100 ml infusion<br />bottle or bag.<br />2. Add this volume to the vial with the freeze-dried omeprazole, mix<br />thoroughly making sure all omeprazole is dissolved.<br />3. Draw the omeprazole solution back into the syringe.<br />4. Transfer the solution into the infusion bag or bottle.<br />5. Repeat steps 1-4 to make sure all omeprazole is transferred from the vial<br />into the infusion bag or bottle.<br />&nbsp;</p><p><u>Alternative preparation for infusions in flexible containers</u><br />1. Use a double-ended transfer needle and attach to the injection membrane<br />of the infusion bag. Connect the other needle-end from the vial with<br />freeze-dried omeprazole.<br />2. Dissolve the omeprazole substance by pumping the infusion solution<br />back and forward between the infusion bag and the vial.<br />3. Make sure all omeprazole is dissolved.</p><p>The solution for infusion is to be administered in an intravenous infusion for 20-<br />30 minutes.<br />Any unused product or waste material should be disposed of in accordance with<br />local requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sofarimex Indústria Química e Farmacêutica, S.A.
Av. das Indústrias- Alto do Colaride-Agualva
2735-213-Cacém
Portugal
For SPIMACO ADDAWAEIH KSA.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>